Top

Archives of Gynecology and Obstetrics

Published in:

Open Access 01-03-2013 | Gynecologic Oncology

MRP2 (ABCC2, cMOAT) expression in nuclear envelope of primary fallopian tube cancer cells is a new unfavorable prognostic factor

Authors: Agnieszka Halon, Verena Materna, Piotr Donizy, Rafal Matkowski, Jerzy Rabczynski, Hermann Lage, Pawel Surowiak

Published in: Archives of Gynecology and Obstetrics | Issue 3/2013

Abstract

Objective

To determine the prognostic value of the immunohistochemical evaluation of the multidrug resistance-associated protein 2 (MRP2) expression, together with its subcellular localization in primary fallopian tube carcinomas (PFTCs).

Methods

The immunohistochemical analysis was performed using samples originating from 70 patients with PFTCs.

Results

(1) We documented that MRP2 can be localized in the plasma membrane (MRP2c), as well as in the nuclear envelope (MRP2n) of the PFTC cells. (2) Patients with more advanced stage, with progression of the disease and patients who died, showed significantly higher expression of the MRP2n. (3) Univariate and multivariate analyses showed that MRP2n is an unfavorable prognostic factor in PFTCs. (4) The analysis of the classic clinicopathological data revealed that only the FIGO stage had prognostic value, both in the univariate, as well as in multivariate analysis.

Conclusions

(1) This study suggests that MRP2n is a new disadvantageous prognostic factor in PFTCs and (2) that expression in nuclear envelope can be associated with lower differentiation of cancer cells and their resistance to the cisplatin. (3) We have also confirmed independent prognostic value of FIGO stage in PFTCs.

Reports based on data of the National Cancer Registry in Poland: http://85.128.14.124/krn/english/index.asp

Stewart SL, Wike JM, Foster SL, Michaud F (2007) The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol 107:392–397PubMedCrossRef

Wethington SL, Herzog TJ, Seshan VE et al (2008) Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. Cancer 113:3298–3306PubMedCrossRef

Hu CY, Taymour ML, Hertig AT (1950) Primary carcinoma of the fallopian tube. Am J Obstet Gynaecol 59:58–67

Sedlis A (1978) Carcinoma of the fallopian tube. Surg Clin North Am 58:121–129PubMed

Ng P, Lawton F (1998) Fallopian tube carcinoma–a review. Ann Acad Med Singapore 27:693–697PubMed

Karst AM, Levanon K, Drapkin R (2011) Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci USA 108:7547–7552PubMedCrossRef

Levanon K, Crum C, Drapkin R (2008) New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26:5284–5293PubMedCrossRef

Alvarado-Cabrero I, Young RH, Vamvakas EC et al (1999) Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol 72:367–379PubMedCrossRef

10.

Baekelandt M, Nesbakken AJ, Kristensen GB et al (2000) Carcinoma of the fallopian tube. Clinicopathologic study of 151 patients treated at the Norwegian Radium Hospital. Cancer 89:2076–2084PubMedCrossRef

11.

Nordin AJ (1994) Primary carcinoma of the fallopian tube: a 20-year literature review. Obstet Gynaecol Surv 49:349–361CrossRef

12.

Hellström AC, Silfverswärd C, Nilsson B et al (1994) Carcinoma of the fallopian tube. A clinical and histopathologic review. The Radiumhemmet series. Int J Gynecol Cancer 4:395–400PubMedCrossRef

13.

Rosen AC, Ausch M, Hafner E et al (1998) A 15-year overview of management and prognosis in fallopian tube carcinoma. Austrian Cooperative Study Group for Fallopian Tube Carcinoma. Eur J Cancer 34:1725–1729PubMedCrossRef

14.

Rabczyński J, Ziółkowski P, Kochman A et al (1998) Primary fallopian tube carcinoma. Histopathology of 46 cases. Pol J Pathol 49:285–292PubMed

15.

Papadimitriou CA, Markaki S, Lianos E et al (2009) Clinicopathological features of primary fallopian tube carcinoma: a single institution experience. Eur J Gynaecol Oncol 30:389–395PubMed

16.

Pectasides D, Pectasides E, Papaxoinis G et al (2009) Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients. Gynecol Oncol 115:97–101PubMedCrossRef

17.

Liapis A, Bakalianou K, Mpotsa E et al (2008) Fallopian tube malignancies: a retrospective clinical pathological study of 17 cases. J Obstet Gynaecol 28:93–95PubMedCrossRef

18.

Rose PG, Shrigley R, Wiesner GL (2000) Germline BRCA2 mutation in patient with primary fallopian tube carcinoma: a case report. Gynecol Oncol 77:319–320PubMedCrossRef

19.

Aziz S, Kuperstein G, Rosen B et al (2001) A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 80:341–345PubMedCrossRef

20.

Pectasides D, Pectasides E, Economopoulos T (2006) Fallopian tube carcinoma: a review. Oncologist 11:902–912PubMedCrossRef

21.

Kosary C, Trimble EL (2002) Treatment and survival for women with fallopian tube carcinoma: a population-based study. Gynecol Oncol 86:190–191PubMedCrossRef

22.

Gadducci A, Landoni F, Sartori E et al (2001) Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study. Gynecol Oncol 81:150–159PubMedCrossRef

23.

Peters WA, Andersen WA, Hopkins MP (1988) Prognostic features of carcinoma of the fallopian tube. Obstet Gynecol 71:757–762PubMed

24.

Kruh GD, Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22:7537–7552PubMedCrossRef

25.

Taniguchi K, Wada M, Kohno K et al (1996) A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56:4124–4129PubMed

26.

Liedert B, Materna V, Schadendorf D et al (2003) Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 121:172–176PubMedCrossRef

27.

Surowiak P, Materna V, Kaplenko I et al (2006) ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res 12:7149–7158PubMedCrossRef

28.

Wada M, Toh S, Taniguchi K et al (1998) Mutations in the canalicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet 7:203–207PubMedCrossRef

29.

Materna V, Stege A, Surowiak P et al (2006) RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem Biophys Res Commun 348:153–157PubMedCrossRef

30.

Kowalski P, Surowiak P, Lage H (2005) Reversal of drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. Mol Ther 11:1393–1398CrossRef

31.

Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140PubMed

32.

Yamasaki M, Makino T, Masuzawa T et al (2011) Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer 104:707–713PubMedCrossRef

33.

Ruggeri RM, Sciacchitano S, Vitarelli E et al (2006) Immunoexpression of multidrug-resistance protein 2 and cyclooxygenase 2 in medullary thyroid carcinomas. Arch Pathol Lab Med 130:1014–1019PubMed

34.

Noma B, Sasaki T, Fujimoto Y et al (2008) Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Int J Oncol 33:1187–1194PubMed

35.

van den Broek GB, Wildeman M, Rasch CR et al (2009) Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer 124:2643–2650PubMedCrossRef

36.

Kim YH, Ishii G, Goto K et al (2009) Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer 65:105–111PubMedCrossRef

37.

Ushijima R, Takayama K, Izumi M et al (2007) Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer. Anticancer Res 27:4351–4358PubMed

38.

Korita PV, Wakai T, Shirai Y et al (2010) Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep 23:965–972PubMed

39.

Rau S, Autschbach F, Riedel HD et al (2008) Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas. Eur J Clin Invest 38:134–142PubMedCrossRef

40.

Sandusky GE, Mintze KS, Pratt SE et al (2002) Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 41:65–74PubMedCrossRef

41.

Chen H, Hao J, Wang L (2009) Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDRI, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101:432–440PubMedCrossRef

42.

Ohishi Y, Oda Y, Uchiumi T et al (2002) ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin Cancer Res 8:3767–3775PubMed

43.

Materna V, Pleger J, Hoffmann U et al (2004) RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 94:152–160PubMedCrossRef

44.

Guminski AD, Balleine RL, Chiew YE et al (2006) MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecol Oncol 100:239–246PubMedCrossRef

45.

Ma JJ, Chen BL, Xin XY (2009) Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene. Arch Gynecol Obstet 279:149–157PubMedCrossRef

Title: MRP2 (ABCC2, cMOAT) expression in nuclear envelope of primary fallopian tube cancer cells is a new unfavorable prognostic factor
Authors: Agnieszka Halon
Verena Materna
Piotr Donizy
Rafal Matkowski
Jerzy Rabczynski
Hermann Lage
Pawel Surowiak
Publication date: 01-03-2013
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 3/2013
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-012-2589-7

At a glance: The STEP trials

Springer Medicine

MRP2 (ABCC2, cMOAT) expression in nuclear envelope of primary fallopian tube cancer cells is a new unfavorable prognostic factor

Abstract

Objective

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2013

What is the success of drug treatment in urge urinary incontinence? What should be measured?

Erratum to: A case with vesicouterine fistula: mini review

A retrospective investigation of women’s experience with breast reconstruction after mastectomy

Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies

Financing of certified centers: a willingness-to-pay analysis

Sequential clomiphene citrate/hMG versus hMG for ovulation induction in clomiphene citrate-resistant women